GlobeNewswire·May 13, 2026, 2:05 AM ET

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

Aligos Therapeutics announced ten abstracts accepted for poster presentations at the EASL Congress 2026 in Barcelona, Spain, held May 27–30, 2026.
The company will present data on pevifoscorvir sodium (ALG-000184), a potential first- or best-in-class capsid assembly modulator for chronic HBV, showing sustained antigen reduction after 96 weeks of monotherapy.
Abstracts detail pevifoscorvir sodium's potent antiviral activity in untreated HBeAg+ subjects, population pharmacokinetics, and the in vitro properties of its parent compound ALG-001075.
Aligos will share findings on ALG-170675, a potential best-in-class antisense oligonucleotide for HBV, demonstrating additive to synergistic effects when combined with other anti-HBV therapies.
Data on ALG-055009, a THR-β agonist for MASH, will be presented regarding synergistic fat mass loss in obese mice when combined with incretin receptor agonists.
Preclinical research on HDV will be shared, including antisense oligonucleotide strategies to target infections and the discovery of novel HDV entry inhibitors.
The company will present preclinical characterization of ALG-093940, a potent oral PD-1/PD-L1 inhibitor for chronic HBV and liver cancer treatment.
All abstracts are accessible on the EASL website, with presentations scheduled across May 27, 28, and 30, 2026.